Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Arrowhead Pharmaceuticals Inc’s stock clocked out at $19.86, down -0.25% from its previous closing price of $19.91. In other words, the price has decreased by -$0.25 from its previous closing price. On the day, 2.06 million shares were traded. ARWR stock price reached its highest trading level at $20.13 during the session, while it also had its lowest trading level at $19.42.
Ratios:
To gain a deeper understanding of ARWR’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.87 and its Current Ratio is at 4.87. In the meantime, Its Debt-to-Equity ratio is 1.37 whereas as Long-Term Debt/Eq ratio is at 1.28.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Goldman on June 05, 2024, initiated with a Neutral rating and assigned the stock a target price of $31.
On December 04, 2023, BofA Securities started tracking the stock assigning a Buy rating and target price of $29.
On September 19, 2023, Citigroup started tracking the stock assigning a Neutral rating and target price of $33.Citigroup initiated its Neutral rating on September 19, 2023, with a $33 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 15 ’25 when Hamilton James C sold 9,389 shares for $20.00 per share. The transaction valued at 187,780 led to the insider holds 262,122 shares of the business.
Hamilton James C sold 611 shares of ARWR for $12,220 on Aug 13 ’25. The Chief Medical Officer now owns 271,511 shares after completing the transaction at $20.00 per share. On Aug 15 ’25, another insider, Hamilton James C, who serves as the Officer of the company, bought 9,389 shares for $20.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARWR now has a Market Capitalization of 2745804032 and an Enterprise Value of 2565314816. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.79 while its Price-to-Book (P/B) ratio in mrq is 5.25. Its current Enterprise Value per Revenue stands at 4.477 whereas that against EBITDA is -30.04.
Stock Price History:
The Beta on a monthly basis for ARWR is 1.00, which has changed by -0.21315372 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ARWR has reached a high of $27.34, while it has fallen to a 52-week low of $9.57. The 50-Day Moving Average of the stock is 17.83%, while the 200-Day Moving Average is calculated to be 13.74%.
Shares Statistics:
It appears that ARWR traded 1.95M shares on average per day over the past three months and 2885270 shares per day over the past ten days. A total of 138.14M shares are outstanding, with a floating share count of 115.22M. Insiders hold about 16.66% of the company’s shares, while institutions hold 74.79% stake in the company. Shares short for ARWR as of 1753920000 were 12937337 with a Short Ratio of 6.65, compared to 1751241600 on 12616251. Therefore, it implies a Short% of Shares Outstanding of 12937337 and a Short% of Float of 12.0900005.
Earnings Estimates
The current rating of Arrowhead Pharmaceuticals Inc (ARWR) reflects the combined expertise of 13.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.41, with high estimates of $0.55 and low estimates of -$1.4.
Analysts are recommending an EPS of between $0.82 and -$1.06 for the fiscal current year, implying an average EPS of -$0.13. EPS for the following year is -$3.39, with 13.0 analysts recommending between -$1.24 and -$4.72.
Revenue Estimates
For the next quarter, 14 analysts are estimating revenue of $140.63M. There is a high estimate of $268.84M for the next quarter, whereas the lowest estimate is $9M.
A total of 16 analysts have provided revenue estimates for ARWR’s current fiscal year. The highest revenue estimate was $923M, while the lowest revenue estimate was $573M, resulting in an average revenue estimate of $741.95M. In the same quarter a year ago, actual revenue was $3.55MBased on 16 analysts’ estimates, the company’s revenue will be $319.57M in the next fiscal year. The high estimate is $564.4M and the low estimate is $94.3M.
